CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis

British Journal of Haematology

Volumn 161, Issue 5, 2013, Pages 649-658

  Grossmann, Vera ^a   Haferlach, Claudia ^a   Nadarajah, Niroshan ^a   Fasan, Annette ^a   Weissmann, Sandra ^a   Roller, Andreas ^a   Eder, Christiane ^a   Stopp, Elisa ^a   Kern, Wolfgang ^a   Haferlach, Torsten ^a   Kohlmann, Alexander ^a   Schnittger, Susanne ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

CEBPA double mutated; Concomitant mutations; Gene expression array; Serial analyses; Survival analysis

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; NUCLEOPHOSMIN; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR RUNX1; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; AGED; ARTICLE; ASXL1 GENE; CANCER PROGNOSIS; CCAAT ENHANCER BINDING PROTEIN ALPHA GENE; CD135 GENE; DNA METHYLTRANSFERASE 3A GENE; FEMALE; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; ISOCITRATE DEHYDROGENASE 1 GENE; ISOCITRATE DEHYDROGENASE 2 GENE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; MUTATOR GENE; NUCLEOPHOSMIN GENE; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; ONCOGENE N RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; TET2 GENE; TRANSCRIPTION FACTOR RUNX1 GENE; WILD TYPE; WT1 GENE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CCAAT-ENHANCER-BINDING PROTEINS; COHORT STUDIES; DNA-BINDING PROTEINS; FEMALE; GATA2 TRANSCRIPTION FACTOR; GENE EXPRESSION PROFILING; GENES, NEOPLASM; GERM-LINE MUTATION; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NEOPLASM PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84877826132     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12297     Document Type: Article

References (28)

1. Bienz, M., Ludwig, M., Mueller, B.U., Leibundgut, E.O., Ratschiller, D., Solenthaler, M., Fey, M.F. & Pabst, T. (2005) Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clinical Cancer Research, 11, 1416-1424.
2. Buchner, T., Hiddemann, W., Wormann, B., Loffler, H., Gassmann, W., Haferlach, T., Fonatsch, C., Haase, D., Schoch, C., Hossfeld, D., Lengfelder, E., Aul, C., Heyll, A., Maschmeyer, G., Ludwig, W.D., Sauerland, M.C. & Heinecke, A. (1999) Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood, 93, 4116-4124.
3. Carmichael, C.L., Wilkins, E.J., Bengtsson, H., Horwitz, M.S., Speed, T.P., Vincent, P.C., Young, G., Hahn, C.N., Escher, R. & Scott, H.S. (2010) Poor prognosis in familial acute myeloid leukaemia with combined biallelic CEBPA mutations and downstream events affecting the ATM, FLT3 and CDX2 genes. British Journal of Haematology, 150, 382-385.
4. Dufour, A., Schneider, F., Metzeler, K.H., Hoster, E., Schneider, S., Zellmeier, E., Benthaus, T., Sauerland, M.C., Berdel, W.E., Buchner, T., Wormann, B., Braess, J., Hiddemann, W., Bohlander, S.K. & Spiekermann, K. (2010) Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. Journal of Clinical Oncology, 28, 570-577.
5. Fasan, A., Eder, C., Haferlach, C., Grossmann, V., Kohlmann, A., Dicker, F., Kern, W., Haferlach, T. & Schnittger, S. (2012) GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis. Leukemia, 27, 482-485.
6. Figueroa, M.E., bdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H.F., Tallman, M.S., Sun, Z., Wolniak, K., Peeters, J.K., Liu, W., Choe, S.E., Fantin, V.R., Paietta, E., Lowenberg, B., Licht, J.D., Godley, L.A., Delwel, R., Valk, P.J., Thompson, C.B., Levine, R.L. & Melnick, A. (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell, 18, 553-567.
7. Flach, J., Dicker, F., Schnittger, S., Schindela, S., Kohlmann, A., Haferlach, T., Kern, W. & Haferlach, C. (2011) An accumulation of cytogenetic and molecular genetic events characterizes the progression from MDS to secondary AML: an analysis of 38 paired samples analyzed by cytogenetics, molecular mutation analysis and SNP microarray profiling. Leukemia, 25, 713-718.
8. Frohling, S., Schlenk, R.F., Stolze, I., Bihlmayr, J., Benner, A., Kreitmeier, S., Tobis, K., Dohner, H. & Dohner, K. (2004) CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. Journal of Clinical Oncology, 22, 624-633.
9. Gombart, A.F., Hofmann, W.K., Kawano, S., Takeuchi, S., Krug, U., Kwok, S.H., Larsen, R.J., Ascou, H., Miller, C.W., Hoelzer, D. & Koeffler, H.P. (2002) Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein α in myelodysplastic syndromes and acute myeloid leukemias. Blood, 99, 1332-1340.
10. Greif, P.A., Dufour, A., Konstandin, N.P., Ksienzyk, B., Zellmeier, E., Tizazu, B., Sturm, J., Benthaus, T., Herold, T., Yaghmaie, M., Dorge, P., Hopfner, K.P., Hauser, A., Graf, A., Krebs, S., Blum, H., Kakadia, P.M., Schneider, S., Hoster, E., Schneider, F., Stanulla, M., Braess, J., Sauerland, M.C., Berdel, W.E., Buchner, T., Woermann, B.J., Hiddemann, W., Spiekermann, K. & Bohlander, S.K. (2012) GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood, 120, 395-403.
11. Grossmann, V., Schnittger, S., Schindela, S., Klein, H.U., Eder, C., Dugas, M., Kern, W., Haferlach, C., Haferlach, T. & Kohlmann, A. (2010) Robust and sensitive detection of insertions, deletions and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing (NGS). Blood, 116, 1657a.
12. Grossmann, V., Schnittger, S., Kohlmann, A., Eder, C., Roller, A., Dicker, F., Schmid, C., Wendtner, C.M., Staib, P., Serve, H., Kreuzer, K.A., Kern, W., Haferlach, T. & Haferlach, C. (2012) A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood, 120, 2963-2972.
13. Kohlmann, A., Haschke-Becher, E., Wimmer, B., Huber-Wechselberger, A., Meyer-Monard, S., Huxol, H., Siegler, U., Rossier, M., Matthes, T., Rebsamen, M., Chiappe, A., Diemand, A., Rauhut, S., Johnson, A., Liu, W.M., Williams, P.M., Wieczorek, L. & Haferlach, T. (2008a) Intraplatform reproducibility and technical precision of gene expression profiling in 4 laboratories investigating 160 leukemia samples: the DACH study. Clinical Chemistry, 54, 1705-1715.
14. Kohlmann, A., Kipps, T.J., Rassenti, L.Z., Downing, J.R., Shurtleff, S.A., Mills, K.I., Gilkes, A.F., Hofmann, W.K., Basso, G., Dell'orto, M.C., Foa, R., Chiaretti, S., De, V.J., Rauhut, S., Papenhausen, P.R., Hernandez, J.M., Lumbreras, E., Yeoh, A.E., Koay, E.S., Li, R., Liu, W.M., Williams, P.M., Wieczorek, L. & Haferlach, T. (2008b) An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase. British Journal of Haematology, 142, 802-807.
15. Koschmieder, S., Halmos, B., Levantini, E. & Tenen, D.G. (2009) Dysregulation of the C/EBPalpha differentiation pathway in human cancer. Journal of Clinical Oncology, 27, 619-628.
16. Ommen, H.B., Schnittger, S., Jovanovic, J.V., Ommen, I.B., Hasle, H., Ostergaard, M., Grimwade, D. & Hokland, P. (2010) Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood, 115, 198-205.
17. Pabst, T. & Mueller, B.U. (2009) Complexity of CEBPA dysregulation in human acute myeloid leukemia. Clinical Cancer Research, 15, 5303-5307.
18. Pabst, T., Eyholzer, M., Haefliger, S., Schardt, J. & Mueller, B.U. (2008) Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. Journal of Clinical Oncology, 26, 5088-5093.
19. Pabst, T., Eyholzer, M., Fos, J. & Mueller, B.U. (2009) Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. British Journal of Haematology, 100, 1343-1346.
20. Quintana-Bustamante, O., Smith, S.L., Griessinger, E., Reyal, Y., Vargaftig, J., Lister, T.A., Fitzgibbon, J. & Bonnet, D. (2012) Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis. Leukemia, 26, 1537-1546.
21. Schaich, M., Rollig, C., Soucek, S., Kramer, M., Thiede, C., Mohr, B., Oelschlaegel, U., Schmitz, N., Stuhlmann, R., Wandt, H., Schafer-Eckart, K., Aulitzky, W., Kaufmann, M., Bodenstein, H., Tischler, J., Ho, A., Kramer, A., Bornhauser, M., Schetelig, J. & Ehninger, G. (2011) Cytarabine dose of 36 g/m(2) compared with 12 g/m(2) within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study. Journal of Clinical Oncology, 29, 2696-2702.
22. Schlenk, R.F., Döhner, K., Krauter, J., Frohling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Spath, D., Morgan, M., Benner, A., Schlegelberger, B., Heil, G., Ganser, A. & Döhner, H. (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. New England Journal of Medicine, 358, 1909-1918.
23. Schnittger, S., Kern, W., Tschulik, C., Weiss, T., Dicker, F., Falini, B., Haferlach, C. & Haferlach, T. (2009) Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood, 114, 2220-2231.
24. Schnittger, S., Alpermann, T., Eder, C., Schindela, S., Grossmann, V., Kern, W., Haferlach, T. & Haferlach, C. (2010) The role of different genetic subtypes in CEBPA mutated AML. Blood, 116, 752a.
25. Sellick, G.S., Spendlove, H.E., Catovsky, D., Pritchard-Jones, K. & Houlston, R.S. (2005) Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia. Leukemia, 19, 1276-1278.
26. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. International Agency for Research on Cancer (IARC), Lyon.
27. Taskesen, E., Bullinger, L., Corbacioglu, A., Sanders, M.A., Erpelinck, C.A., Wouters, B.J., van der Poel-van de Luytgaarde, SC, Damm, F., Krauter, J., Ganser, A., Schlenk, R.F., Lowenberg, B., Delwel, R., Dohner, H., Valk, P.J. & Dohner, K. (2011) Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood, 117, 2469-2475.
28. Wouters, B.J., Lowenberg, B., Erpelinck-Verschueren, C.A., van Putten, W.L., Valk, P.J. & Delwel, R. (2009) Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood, 113, 3088-3091.